Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations

Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer. Their low sensitivity and specificity preclude the use of serum markers such as the MUC-1 mucin glycoproteins (CA 15.3, BR 27.29) and carcinoembryonic antigen in the diagnosis of early breast cancer. However, serial measurement of these markers can result in the early detection of recurrent disease as well as indicate the efficacy of therapy. Of the tissue-based markers, measurement of estrogen and progesterone receptors is mandatory in the selection of patients for treatment with hormone therapy, while HER-2 is essential in selecting patients with advanced breast cancer for treatment with Herceptin (trastuzumab). Urokinase plasminogen activator and plasminogen activator inhibitor 1 are recently validated prognostic markers for lymph node-negative breast cancer patients and thus may be of value in selecting node-negative patients that do not require adjuvant chemotherapy.

[1]  M. Duffy,et al.  Predictive markers in breast and other cancers: a review. , 2005, Clinical chemistry.

[2]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[3]  M. Melisko A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer , 2005 .

[4]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[5]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.

[6]  J. Kurebayashi [Tumor markers in breast cancer]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

[7]  M. Untch,et al.  Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. , 2004, Journal of the National Cancer Institute.

[8]  B. Nakata,et al.  Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer , 2004, British Journal of Cancer.

[9]  M. Duffy,et al.  High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. , 2004, Clinical chemistry.

[10]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[11]  J. Gustafsson,et al.  Update on estrogen signaling , 2003, FEBS letters.

[12]  V. Jordan,et al.  The estrogen receptor: a model for molecular medicine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  M. Wyss,et al.  [18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer , 2003, Journal of Cancer Research and Clinical Oncology.

[14]  M. Nap,et al.  Her2/neu analysis in formalin-fixed, paraffin-embedded breast carcinomas: comparison of immunohistochemistry and multiparameter DNA flow cytometry. , 2003, Anticancer research.

[15]  R. Molina,et al.  Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. , 2003, Anticancer research.

[16]  R. Molina,et al.  Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. , 2003, Anticancer research.

[17]  P. Bendahl,et al.  Estrogen and Progesterone Receptor Assay in Paraffin-Embedded Breast Cancer , 2003, Acta oncologica.

[18]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[19]  P. Drew,et al.  Molecular prognostic indicators in breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  I. Smith,et al.  The development and clinical use of trastuzumab (Herceptin). , 2002, Endocrine-related cancer.

[21]  C. Hudis,et al.  Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Untch,et al.  Serum CEA and CA 15-3 as prognostic factors in primary breast cancer , 2002, British Journal of Cancer.

[23]  B. Leyland-Jones Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.

[24]  R. Blamey Guidelines on endocrine therapy of breast cancer EUSOMA. , 2002, European journal of cancer.

[25]  J. Bergh,et al.  C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. , 2002, European journal of cancer.

[26]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[27]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[28]  G. Sölétormos,et al.  Computer-simulated tumor-marker data used to compare progression criteria for cytokeratin tissue polypeptide antigen in metastatic breast cancer. , 2001, Clinical chemistry.

[29]  K. Korach,et al.  The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling* , 2001, The Journal of Biological Chemistry.

[30]  A. Pecking,et al.  Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. , 2001, Clinical breast cancer.

[31]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  F. Guadagni,et al.  A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[34]  M. Leers,et al.  Steroid Receptor Heterogeneity in Relation to DNA Index in Breast Cancer: A Multiparameter Flow Cytometric Approach on Paraffin‐Embedded Tumor Samples , 2001, The breast journal.

[35]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[36]  D. Hayes,et al.  When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Isaacs,et al.  New prognostic factors for breast cancer recurrence. , 2001, Seminars in oncology.

[39]  D. Slamon,et al.  Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. , 2001, Seminars in oncology.

[40]  J. Robertson,et al.  CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. , 2001, European journal of cancer.

[41]  P. Ferrari,et al.  The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer , 2000, British Journal of Cancer.

[42]  S. Gleixner,et al.  Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients. , 2000, Anticancer research.

[43]  H. Grimes,et al.  The Prognostic Value of the Tumor Marker CA 15–3 at Initial Diagnosis of Patients with Breast Cancer , 2000, The International journal of biological markers.

[44]  J. Lydon,et al.  Progesterone receptors in reproduction: functional impact of the A and B isoforms , 2000, Steroids.

[45]  M. Piccart,et al.  HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients? , 2000, European journal of cancer.

[46]  D Barnes,et al.  Immunohistochemical detection of steroid receptors in breast cancer: a working protocol , 2000, Journal of clinical pathology.

[47]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[48]  G. Sölétormos,et al.  Progression criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data. , 2000, Clinical chemistry.

[49]  A. Nicolini,et al.  Postoperative Follow-Up of Breast Cancer Patients: Overview and Progress in the Use of Tumor Markers , 2000, Tumor Biology.

[50]  M. Nap,et al.  A novel flow cytometric steroid hormone receptor assay for paraffin-embedded breast carcinomas: an objective quantification of the steroid hormone receptors and direct correlation to ploidy status and proliferative capacity in a single-tube assay. , 2000, Human pathology.

[51]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[52]  R. Molina,et al.  Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse. , 1999, Anticancer research.

[53]  M. Untch,et al.  Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis. , 1999, Anticancer research.

[54]  M. Duffy,et al.  Urokinase plasminogen activator: A prognostic marker in multiple types of cancer , 1999, Journal of surgical oncology.

[55]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  N. Brünner,et al.  External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. , 1998, British Journal of Cancer.

[57]  R. Molina,et al.  c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value , 1998, Breast Cancer Research and Treatment.

[58]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[59]  K Vajda,et al.  [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.

[60]  A. van Dalen,et al.  The Prognostic Significance of Increasing Marker Levels in Metastatic Breast Cancer Patients with Clinically Complete Remission, Partial Remission or Stable Disease , 1998, The International journal of biological markers.

[61]  O. Nilsson,et al.  Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 Mucin , 1997, Tumor Biology.

[62]  N. Ordóñez Value of thrombomodulin immunostaining in the diagnosis of transitional cell carcinoma: a comparative study with carcinoembryonic antigen , 1997, Histopathology.

[63]  M. Krieg,et al.  A multicentre evaluation of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay on the Bayer Immuno 1 System. , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[64]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[65]  D. Chan,et al.  Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  L. Norton,et al.  HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. , 1997, Oncology.

[67]  B A Miller,et al.  Recent trends in U.S. breast cancer incidence, survival, and mortality rates. , 1996, Journal of the National Cancer Institute.

[68]  D. Barnes,et al.  Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.

[69]  R. Molina,et al.  Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. , 1996, British Journal of Cancer.

[70]  C. Sturgeon,et al.  Why do immunoassays for tumour markers give differing results?--a view from the UK National External Quality Assessment Schemes. , 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[71]  N. Brünner,et al.  Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. , 1996, European journal of cancer.

[72]  A. V. Dalen Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. , 1996 .

[73]  J. Feldman,et al.  Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol‐based ligand‐binding assays , 1996, Cancer.

[74]  C. Sturgeon,et al.  Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes , 1996 .

[75]  P. Dombernowsky,et al.  Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. , 1996, Clinical chemistry.

[76]  W. Willett,et al.  Pregnancy termination in relation to risk of breast cancer. , 1996, JAMA.

[77]  Anthony Howell,et al.  Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. , 1995, The New England journal of medicine.

[78]  Mike Clarke,et al.  EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS , 1995 .

[79]  Ronin,et al.  Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. , 1995, The New England journal of medicine.

[80]  J Benichou,et al.  Proportion of breast cancer cases in the United States explained by well-established risk factors. , 1995, Journal of the National Cancer Institute.

[81]  R. Blamey,et al.  Potential for cost economies in guiding therapy in patients with metastatic breast cancer. , 1995, British Journal of Cancer.

[82]  M. McGuckin,et al.  CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer , 1995, Breast Cancer Research and Treatment.

[83]  M. Kerin,et al.  An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. , 1995, British Journal of Cancer.

[84]  I. Tomlinson,et al.  Tumour marker CA15-3: possible uses in the routine management of breast cancer. , 1995, European journal of cancer.

[85]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[86]  E. Vizcarra,et al.  CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. , 1994, Oncology.

[87]  M. Indelli,et al.  Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. , 1994, JAMA.

[88]  S. Ciatto,et al.  Intensive Diagnostic Follow-up After Treatment of Primary Breast Cancer: A Randomized Trial , 1994 .

[89]  S. Ciatto,et al.  Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. , 1994, JAMA.

[90]  A. Clerico,et al.  Analytical Performance of Ca 19.9, Ca 125 and Ca 15.3 Assays as Observed through an External Quality Assessment Program , 1994, The International journal of biological markers.

[91]  H. Mouridsen,et al.  A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  A. Vandalen,et al.  How can treatment response be measured in breast cancer patients , 1993 .

[93]  J. Manson,et al.  Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. , 1993, JAMA.

[94]  R. Blamey,et al.  Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? , 1993, British Journal of Cancer.

[95]  A. Luini,et al.  Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. , 1993, The New England journal of medicine.

[96]  D. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.

[97]  H. Adami,et al.  Evidence of prenatal influences on breast cancer risk , 1992, The Lancet.

[98]  Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[99]  M. Inbar,et al.  Serial serum MCA measurements in the follow-up of breast cancer patients. , 1991, European journal of cancer.

[100]  A. Howell,et al.  Objective measurement of therapeutic response in breast cancer using tumour markers. , 1991, British Journal of Cancer.

[101]  A. Dnistrian,et al.  CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[102]  E. Röttinger,et al.  The value of the tumor marker CA 15‐3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen , 1991, Cancer.

[103]  A. Nicolini,et al.  Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. , 1991, British Journal of Cancer.

[104]  M. Gion,et al.  The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. , 1991, British Journal of Cancer.

[105]  N. Urban,et al.  A minimalist policy for breast cancer surveillance. , 1991, JAMA.

[106]  G. Greene,et al.  Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival , 1990, Cancer.

[107]  M. Duffy Biochemical markers as prognostic indices in breast cancer. , 1990, Clinical chemistry.

[108]  G. Hortobagyi,et al.  The Role of Serum CEA as a Prognostic Indicator in Stage II and III Breast Cancer Patients Treated With Adjuvant Chemotherapy , 1989, Cancer.

[109]  K. Holli,et al.  Effectiveness of routine and spontaneous follow-up visits for breast cancer. , 1989, European journal of cancer & clinical oncology.

[110]  M. Williams,et al.  The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[111]  R. Gelman,et al.  Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. , 1988, Cancer research.

[112]  S. Palazzo,et al.  Is the Carcinoembryonic Antigen Test a Valid Predictor of Response to Medical Therapy in Disseminated Breast Cancer? , 1986, Tumori.

[113]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[114]  L. Tabár,et al.  REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare , 1985, The Lancet.

[115]  G. Hortobagyi,et al.  Complete remissions in metastatic breast cancer treated with combination drug therapy. , 1979, Annals of internal medicine.

[116]  N. Harbeck,et al.  Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. , 2006, Methods in molecular medicine.

[117]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[118]  H. Iwata,et al.  Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer , 2004, Breast Cancer Research and Treatment.

[119]  L. Dušek,et al.  Breast cancer and neoadjuvant therapy: any predictive marker? , 2004, Neoplasma.

[120]  M. Kurosumi,et al.  Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: A prospective study , 2004, Breast cancer.

[121]  M. Morrow Identification and management of the woman at increased risk for breast cancer development , 2004, Breast Cancer Research and Treatment.

[122]  Martín Velasco,et al.  Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients , 2004, Breast Cancer Research and Treatment.

[123]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[124]  D. Chan,et al.  Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. , 2003, Clinical laboratory.

[125]  M. Duffy Urokinase Plasminogen Activator and Its Inhibitor, Pai-1, as Prognostic Markers in Breast Cancer: from Pilot to Level 1 Evidence Studies , 2002 .

[126]  A. van Dalen Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. , 1996, Anticancer research.

[127]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[128]  H. D. de Koning,et al.  Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. , 1995, Journal of the National Cancer Institute.

[129]  A. van Dalen,et al.  How can treatment response be measured in breast cancer patients? , 1993, Anticancer research.

[130]  A. van Dalen TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3. , 1992, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[131]  A. V. Dalen TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3. , 1992 .

[132]  Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992, Lancet.

[133]  C. Bieglmayer,et al.  CA15.3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. , 1991, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[134]  A. Dnistrian,et al.  Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. , 1991, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[135]  J. Brockschmidt,et al.  Postoperative follow‐up of patients with early breast cancer. Patterns of care among clinical oncologists and a review of the literature , 1991, Cancer.

[136]  A. V. Dalen Pre-operative tumour marker levels in patients with breast cancer and their prognosis. , 1990 .

[137]  A. van Dalen Pre-operative tumour marker levels in patients with breast cancer and their prognosis. , 1990, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[138]  C. Rose,et al.  Oestrogen and progesterone receptor determinations in breast cancer: technology and biology. , 1986, Cancer surveys.

[139]  C. Loprinzi,et al.  Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  J. Lindeman,et al.  Estrogen receptors in human breast cancer , 1982, Virchows Archiv. B, Cell pathology including molecular pathology.

[141]  R. Lamerz,et al.  Serial carcinoembryonic antigen (CEA) determinations in the management of metastatic breast cancer. , 1980, Oncodevelopmental biology and medicine : the journal of the International Society for Oncodevelopmental Biology and Medicine.